CLAIMS

1. Use of a composition for the manufacture of a medicament for treating a disease or disorder, wherein the composition is to be administered once daily to a subject, preferably a human, in need thereof, wherein the composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, and wherein the compound has an enantiomeric excess (ee) of the (R) form higher than or equal to about 99%.

2. Use of claim 1, wherein the composition is to be administered once daily to the subject in need thereof for at least eight weeks.

3. Use of any of claim 1 or 2, wherein the disease or disorder is a chronic disease or disorder, preferably a chronic cardiovascular disease or disorder.

4. Use of any one of the preceding claims, wherein the composition is to be administered once daily to the subject at a dosage from 1 mg to 12 mg of the compound.

5. Use of any one of the preceding claims, wherein the compound is to be administered at a dosage of about 4 mg.

6. Use of any one of claims 1-4, wherein the compound is to be administered at a dosage of about 8 mg.

7. Use of any one of the preceding claims, wherein the compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, preferably wherein said (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate has an enantiomeric excess (ee) of the (R) form higher than or equal to about 99.5%, more preferably higher than or equal to about 99.9%.

8. Use of any one of the preceding claims, wherein the disease or disorder is selected from the group consisting of primary aldosteronism, secondary aldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial

infarction, renal fibrosis, coronary heart disease, sodium retention, water retention, hypokalemia, hypomagnesaemia, hypertension, left ventricular hypertrophy, cardiac fibrosis, cardiovascular damage, suppression of plasma renin, kidney fibrosis, arrhythmias, nephropathy, edema, hypokalemia-caused muscle weakness, cardiac fibrillation and weakened cardiac muscle contraction;

preferably wherein the disease or disorder is selected from the group consisting of primary aldosteronism, secondary aldosteronism, heart failure, chronic renal failure, hypertension, restenosis, obesity, nephropathy, post-myocardial infarction, renal fibrosis, coronary heart disease, sodium retention, water retention, hypokalemia, hypomagnesaemia, hypertension, left ventricular hypertrophy, cardiac fibrosis, cardiovascular damage, suppression of plasma renin, kidney fibrosis, arrhythmias, nephropathy, and edema.

9. Use of any one of the preceding claims, the disease or disorder is primary aldosteronism.

10. Use of any one of the preceding claims, wherein the disease or disorder is bilateral primary aldosteronism.

11. Use of any one of claims 1-9, wherein the disease or disorder is unilateral primary aldosteronism, preferably wherein said unilateral primary aldosteronism is caused by unilateral adenoma, unilateral nodules, or unilateral hyperplasia.

12. Use of any one of claims 1-8, wherein the disease or disorder is essential hypertension and/or resistant hypertension, preferably wherein said the disease or disorder is essential hypertension and/or resistant hypertension with accompanying hypokalemia.

13. Use of any one of claims 1-8, wherein the disease or disorder is hypokalemia.

14. Use of any one of the preceding claims, wherein said once daily dose does not require dose adjustment.

15. Use of any one of the preceding claims, wherein the subject exhibits a clinical response within about 14 days of treatment, preferably wherein the clinical response is selected from reduction in plasma aldosterone levels, normalization of plasma aldosterone

levels, reduction of blood pressure, normalization of blood pressure, reduction of hypokalemia, normalization of potassium concentration, and reduction of urinary THA.